EscaZyme Biochemicals, LLC — Department of Health and Human Services STTR Phase I: N

EscaZyme Biochemicals, LLC — STTR Phase I award from Department of Health and Human Services.

Amount
$121,978
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
STTR · Phase I
Topic
N
Solicitation
PA16-303
NAICS
Place of performance
NV
Period
2017-09-30 → 2018-09-29

Description

Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostly overseas The purity and reliability of these sources is highly variable A synthetic source for lutein would ensure quality and secure adequate supplies for the predicted ever increasing demand for this eye health product However there is no commercially viable synthesis of the natural enantiomerically correct form R andapos R andapos R of lutein This barrier prevents the development of a secure reliable and scalable source for lutein Furthermore the unavailability of pure synthetic isomers prevents definitive experimental studies on their relative effectiveness The current proposal seeks to remove this barrier by demonstrating a reliable synthesis of enantiomerically correct lutein and zeaxanthin The hypothesis is that highly enantiomerically enriched S ipsdienol or R ipsdienol can be used to synthesize nature identical lutein or zeaxanthin respectively We have developed an innovative enzymatic process that eliminates the current prohibitively high cost to produce enantiomerically enriched ipsdienol Furthermore we will optimize production of recombinant enzymes used in our process further reducing costs Completion of this Phase I project will show the practicality of new production methods for lutein and zeaxanthin This should lead to significant price reductions for highly pure forms of these chemicals thus enabling further research into their protective properties Phase II efforts will confirm the bioactivity of our products and confirm that possible contaminants in natural preparations do not confer the protective effects assigned to lutein and zeaxanthin We will also seek to expand the potential market for these chemicals as food supplements Project Narrative Lutein and zeaxanthin are recommended as dietary supplements for people at risk of developing late onset macular degeneration AMD The proposed research will investigate the feasibility of a new method to synthesize pure lutein isomers from scratch creating both a valuable research tool as well as a potential alternative source of nature identical lutein and zeaxanthin